Drug Trial Radar · NCT00455533
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
Last checked: Nov 20, 2026Latest source record: Feb 24, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
384
Actual
Start
Oct 2007
Primary completion
Dec 2009
Study completion Dec 2009
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Apr 3, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the effectiveness of ixabepilone when given after doxorubicin plus cyclophosphamide (AC) compared to standard treatment of paclitaxel given after doxorubicin plus cyclophosphamide in patients with early stage breast cancer. In addition the study will verify predefined biomarkers as well as discover new biomarkers that could identify patients who are more likely to respond to ixabepilone than standard paclitaxel based therapy.
Conditions
- Breast Cancer
Interventions
IxabepiloneDrug
Intravenous Solution, intravenous (IV), 40mg/m², Day 1 every 21 days, 12 Weeks
PaclitaxelDrug
Intravenous Solution, IV, 80mg/m², Weekly, 12 Weeks
CyclophosphamideDrug
Intravenous Solution, IV, 600mg/m², Day 1 every 21 days, 12 Weeks
DoxorubicinDrug
Intravenous Solution, IV, 60mg/m², Day 1 every 21 days, 12 Weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Pathologic Complete Response (pCR)Time frame: at surgery (performed 4-6 weeks after the last dose of 12 weeks of therapy)
- Percentage of Participants Achieving Pathologic Complete Response (pCR) in Biomarker-Defined PopulationsTime frame: pCR evaluated at time of surgery (4-6 weeks after the last dose of therapy); mandatory tumor tissue biopsy obtained prior to treatment.
- Percentage of Participants Achieving Pathologic Complete Response (pCR) in 20- and 26-Gene Model SubgroupsTime frame: pCR evaluated at time of surgery (4-6 weeks after the last dose of therapy); mandatory tumor tissue biopsy obtained prior to treatment.
Locations
49 sites in 15 countries. Site status is shown where the registry gives one.
Comprehensive Cancer Center
Palm Springs, California
Northwest Oncology & Hematology Associates
Coral Spring, Florida
Florida Cancer Research Institute
Davie, Florida
Medical Specialists Of Palm Beaches
Lake Worth, Florida
Moffitt Cancer Center
Tampa, Florida
University Medical Center, Inc
Louisville, Kentucky
University Of New Mexico Cancer Center
Albuquerque, New Mexico
Albert Einstein Cancer Center
The Bronx, New York
Virginia Mason Medical Center
Seattle, Washington
Providence Cancer Center
Spokane, Washington
Local Institution
Buenos Aires, Buenos Aires, Argentina
Local Institution
Buenos Aires, Buenos Aires, Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina
Local Institution
Salzburg, Austria
Local Institution
Vienna, Austria
Local Institution
Bordeaux, France
Local Institution
Saint-Herblain, France
Local Institution
Düsseldorf, Germany
Local Institution
Erlangen, Germany
Local Institution
Jena, Germany
Local Institution
Bhopal, India
Local Institution
Hyderabad, India
Local Institution
Mumbai, India
Local Institution
Vellore, India
Local Institution
Bangalore, Karnataka, India
Local Institution
Trivandrum, Kerala, India
Local Institution
Pune, Maharashtra, India
Local Institution
New Delhi, National Capital Territory of Delhi, India
Local Institution
Bologna, Italy
Local Institution
Lima, Lima Province, Peru
Local Institution
Lima, Lima Province, Peru
Local Institution
Callao, Provincia Constitucional del Callao, Peru
Local Institution
Cebu City, Philippines
Local Institution
Davao City, Philippines
Local Institution
Quezon City, Philippines
Local Institution
Kazan', Russia
Local Institution
Moscow, Russia
Local Institution
Saint Petersburg, Russia
Local Institution
Singapore, Singapore
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.